First-in-human phase 1 randomized trial with the anti-CD40 monoclonal antibody KPL-404: safety, tolerability, receptor occupancy, and suppression of T-cell-dependent antibody response - Samant, M; Ziemniak, J; Paolini, J F (J Pharmacol Exp Ther, 2023)